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As many as 90% of adults in the US harbor latent herpes 
simplex virus type 1 or type 2 (HSV-1, HSV-2) infections 
[1]. HSV-1 causes cold sores in and around the mouth, geni-
tal herpes, encephalitis, and corneal disease. In the US, HSV-
1 is the leading cause of corneal blindness due to an infec-
tious agent [2]. HSV-1-induced corneal blindness is due to 
scarring of the cornea, mostly in response to recurrent rather 
than primary infection. Following a primary ocular HSV-1 
infection the virus enters sensory nerves and travels to the 
nerve bodies located in the trigeminal ganglia (TG). Here, 
life long viral latency is established. Sporadic viral reactiva-
tions can occur throughout the life of the infected individual, 
at which time virus returns to, is shed at the ocular surface, 
and can cause recurrent disease leading to loss of vision. Un-
derstanding the molecular mechanisms by which the HSV-1 
latency-reactivation cycle is regulated is therefore important 
for the eventual control and elimination of recurrent herpetic 
disease.
During neuronal latency the latency associated transcript, 
or LAT gene, is the only abundantly transcribed viral gene [3 
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Abstract
The herpes simplex virus type 1 (HSV-1) latency associated transcript (LAT) gene has anti-apoptosis activity that directly or indirectly en-
hances the virus’s reactivation phenotype in small animal models. The first 1.5 kb of the primary 8.3 kb LAT is sufficient and some or all of it is 
necessary for LAT’s anti-apoptosis in transient transfection assays and for LAT’s ability to enhance the reactivation phenotype. Based on LAT’s 
genomic sequence, the first 1.5 kb contains eight potential open reading frames (ORFs) defined as an ATG followed by an in frame termination 
codon. In this study, point mutations were introduced into the ATGs of ORFs present in the 1.5 kb fragment of LAT. Mutagenesis of all eight 
ATGs in LAT ORFs consistently reduced the anti-apoptotic activity of LAT in transiently transfected mouse neuroblastoma cells regardless of 
whether apoptosis was induced by caspase 8 or caspase 9. Mutation of the six ATGs located in the stable intron sequences within the 1.5 kb 
LAT had a dramatic effect on caspase 9, but not caspase 8, induced apoptosis. For both caspase 8 and caspase 9 induced apoptosis, mutating the 
two ATGs in the exon of the LAT 1.5 kb fragment reduced, but did not eliminate the anti-apoptotic activity of LAT. These studies suggest that 
altering the fine structure of regulatory RNA or expression of a putative LAT ORF regulates the anti-apoptosis activity of LAT. These studies 
also indicate that more than one function is present in the 1.5 kb LAT fragment. 
Keywords: herpes simplex virus, HSV-1, LAT, latency, latency associated transcript, apoptosis
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& 4]. LAT plays an important role in the HSV latency-reac-
tivation cycle since LAT null mutants have significantly re-
duced reactivation phenotypes in mice and rabbits while oth-
erwise having wild-type like replication [5–11]. LAT has 
anti-apoptosis activity [12–19]. Mutants in which LAT is re-
placed by an alternative anti-apoptosis gene have efficient, 
wild-type like reactivation phenotypes [20–22], indicating 
that LAT’s anti-apoptosis activity is sufficient to account for 
LAT’s ability to support the wild-type reactivation phenotype 
in experimental animal models.
The mechanism by which LAT’s anti-apoptosis activ-
ity enhances the reactivation phenotype remains to be eluci-
dated. In addition, how LAT’s anti-apoptosis activity is me-
diated also remains to be fully elucidated. However, the most 
critical LAT functions appear to be encoded within the first 
1.5 kb of LAT, since the first 1.5 kb of the primary 8.3 kb pri-
mary LAT (approximately the first 18%) is sufficient for both 
supporting a wild-type virus reactivation phenotype [23] and 
for efficiently blocking apoptosis in transient transfection as-
says [13 & 16].
Based on sequence analysis of the LAT DNA, the first 
1.5 kb of LAT contains eight potential open reading frames 
(ORFs; an ATG followed by an in frame stop codon). How-
ever, the nucleotide sequence in this region is more highly 
conserved among functional LATs from three different HSV-
1 strains ( > 95%) than are the predicted amino acid se-
quences (< 80%). This suggests that there is more selective 
pressure to maintain the RNA sequence than protein coding 
sequences, suggesting that this region of LAT does not en-
code an important functional protein. We therefore proposed 
that LAT functions via its RNA rather than via a LAT pro-
tein. Consistent with this, it was recently reported that LAT 
encodes a miRNA that has anti-apoptosis activity [17]. How-
ever, this miRNA is unlikely to account for LAT’s full func-
tion as it is encoded from a location that is neither essential 
for [15 & 24], nor sufficient for [13] LAT’s ability to block 
apoptosis or enhance the reactivation phenotype. Thus, this 
miRNA does not rule out the possibility of a LAT protein or 
additional regulatory RNAs.
The work presented here was initiated in the hope of dem-
onstrating that none of the potential eight LAT ORFs dis-
cussed above play a role in the ability of LAT to block apop-
tosis and by extension also not involved in LAT’s ability to 
enhance the viral reactivation phenotype. Surprisingly, we re-
port here that changing the relevant ATGs to TTGs to knock 
out expression of these putative proteins had a significant im-
pact on LAT’s anti-apoptosis activity.
We constructed three mutant LAT plasmids (Figure 1), the 
parental plasmid of which (LAT3.3A) contains LAT nts −1801 
to +1499 [13 & 23]. The presence of the entire LAT promoter 
results in this plasmid expressing high levels of the first 1.5 kb 
of LAT following transfection of tissue culture cells. It should 
also be noted that LAT3.3A does not encode the entire stable 
2 kb LAT intron, but still maintains high levels of anti-apop-
tosis activity. In plasmid LAT3.3E, the first two LAT ATGs 
were mutated to TTG, thereby knocking out both of the poten-
tial ORFs located within the exon (LAT nts 1–660). In plas-
mid LAT3.3I, all six potential ORFs within the region of the 
Figure 1. LAT-derived plasmids. (A) LAT3.3A, the parental plasmid, contains LAT nts −1801 to +1499 relative to the start of LAT transcription. It therefore con-
tains the entire LAT promoter and upstream control sequences and transcribes the first 1.5 kb of the primary 8.3 kb LAT. Nts +1 to 661 correspond to the first 
LAT exon. Nts 662–1499 correspond to the first 837 nts of the 2 kb stable LAT intron. The solid rectangles show the relative locations of all eight potential ORFs 
(ATG followed by an in frame stop codon) within the first 1499 nts of the primary LAT transcript. The nt positions of the ORFs relative to the start of LAT tran-
scription at LAT nt +1 are: ORF 1 = nts 217–376; ORF 2 = nts 486–669; ORF 3 = nts 916–1123; ORF 4 = 980–1079; ORF 5 = nts 1091–1298; ORF 6 = 1167–
1242; ORF 7 = 1279–1360; ORF 8 = 1365–1497 [29]. All of the other plasmids are identical to LAT3.3A except for knock out of various ORFs by mutation 
of the relevant ATG to TTG by PCR site directed mutation. All changes were confirmed by complete sequencing of the final DNA fragments. (B) LAT3.3E is 
knocked out for ORF 1 and ORF 2 in the exon but retains all six ORFs in the first 878 nts of the 2 kb intron. (C) LAT3.3I is knocked out for all six ORFs in the 
intron but retains both ORFs in the exon. (D) LAT3.3U is knocked out for all eight ORFs. 
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first 2 kb LAT that is located within the first 1.5 kb of the LAT 
transcript (LAT nts 661–1499) were similarly knocked out. All 
eight potential ORFs were similarly knocked out in LAT3.3U. 
In mammals, there are two major apoptotic pathways; the 
death receptor-mediated pathway or the mitochondrial path-
way [25–27]. The receptor-mediated death pathway activates 
caspase 8, which induces a caspase cascade including caspase 
3. Activation of the mitochondrial death pathway results in re-
lease of several important proapoptotic molecules, including 
cytochrome C and Smac/Diablo [27]. Released cytochrome C 
associates with Apaf-1 leading to caspase 9 activation, which 
culminates in activation of the effector caspases (including 
caspase 3). Thus, it was important to compare the results ob-
tained with caspase 8 induced apoptosis to those obtained by 
inducing apoptosis with caspase 9.
Consequently, Neuro-2A cells were transfected with each 
of the LAT plasmids plus a plasmid that induces apoptosis 
by expressing caspase 8 (Figure 2). Cell survival was deter-
mined 48 h later as previously described [15 & 16]. The num-
ber of cells in control cultures transfected with the same total 
amount of empty plasmid (no LAT; no caspase 8) was set to 
100%. Approximately, 38% of cells survived with the caspase 
8 plasmid alone. As we previously reported, LAT3.3A signif-
icantly protected against caspase 8 induced death (90% sur-
vival; P < 0.05 versus caspase 8, ANOVA two way analysis 
of variance). LAT3.3E, LAT3.3I, and LAT3.3U all had signif-
icantly less survival than the control and LAT3.3A (P < 0.05). 
LAT3.3U did not appear to provide any protection against 
caspase 8 induced apoptosis (P > 0.05) and was significantly 
different from all of the other plasmids (P < 0.05). LAT3.3E 
and LAT3.3I both appeared to provide intermediate protec-
tion as they were each significantly different from the con-
trol, LAT3.3A, and caspase 8 (P < 0.05) but were not different 
from each other (P > 0.05). Thus, knocking out either ORFs 
1 and 2 (LAT3.3E), ORFs 3–8 (LAT3.3I), or all eight ORFs 
appeared to reduce the protective effect of LAT against cas-
pase 8 induced death. Knocking out all eight ORFs appeared 
to more effectively prevent LAT’s anti-apoptosis activity than 
knocking out just ORFs 1–2 or just ORFs 3–8. 
To determine the effects of these ORF knockouts on cas-
pase 9 induced apoptosis, experiments performed as above 
were done using a caspase 9, rather than a caspase 8, express-
ing plasmid to induce apoptosis (Figure 3). Caspase 9 re-
duced cell survival to approximately 30% of the control. As 
with caspase 8 induced apoptosis, the intact LAT3.3A plas-
mid efficiently blocked caspase 9 induced cell death (P < 0.05 
Figure 2. Inhibition of caspase 8 induced apoptosis by LAT constructs. Us-
ing our standard apoptosis blocking assay [15 & 16] Neuro2A cells were co-
transfected with a caspase 8 expressing plasmid to induce apoptosis and one 
of the LAT expressing plasmids (LAT3.3A, LAT3.3E, LAT3.3I, or LAT3.3U). 
Control cells were transfected with the same total amount of empty plasmid. 
Caspase 8 cells were co-transfected with the caspase 8 plasmid and the same 
amount of empty plasmid used in the various LAT samples. Each bar repre-
sents the average±S.E. of three independent experiments, each done at least 
in triplicate. 
Figure 3. Inhibition of caspase 9 induced apoptosis by LAT constructs. Ex-
periments were done as described for Figure 2, except that a caspase 9 ex-
pressing plasmid was used instead of a caspase 8 expressing plasmid. Each 
bar represents the average±S.E. of four independent experiments, each done 
at least in triplicate. 
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versus caspase 9). As with caspase 8 induced apoptosis, the 
LAT3.3E plasmid, knocked out for the first two ORFs, pro-
vided intermediate protection. LAT3.3E provided significant 
protection against caspase 9 induced apoptosis (P < 0.05), 
but the protection was significantly less than that provided 
by LAT3.3A (P < 0.05). In contrast to the caspase 8 results, 
LAT3.3I was significantly different from LAT3.3E (P < 0.05) 
and did not appear to provide any protection against caspase 
9 induced apoptosis (P > 0.05). On the other hand, as for cas-
pase 8 induced apoptosis LAT3.3U did not appear to provide 
any protection against caspase 9 induced apoptosis. LAT3.3U 
was not significantly different from caspase 9 (P > 0.05), 
but was significantly different from the control, LAT3.3A, 
or LAT3.3E (P < 0.05). Thus, as with protection against cas-
pase 8 induced apoptosis, knocking out either ORFs 1 and 
2, ORFs 3–8, or all eight ORFs, appeared to reduce the abil-
ity of LAT to interfere with apoptosis. Knocking out all eight 
ORFs appeared to more effectively inhibit LAT’s anti-apopto-
sis activity compared to knocking out just the first two ORFs. 
Knocking out just ORFs 1 and 2 produced intermediate pro-
tection, while knocking out all eight ORFs or just ORFs 3–8, 
appeared to completely block LAT’s ability to block caspase 
9 induced apoptosis. 
The above results show that preventing or knocking out 
potential protein synthesis from the 8 potential LAT ORFs lo-
cated within the functional first 1.5 kb of LAT can reduce that 
ability of a LAT plasmid to block apoptosis induced by either 
caspase 8 or caspase 9. However, whether these results indi-
cate that there is one of more LAT protein involved in LAT’s 
anti-apoptosis activity remains unclear. These experiments 
were undertaken with the expectation that knocking out the 
LAT ORFs by introducing single nucleotide changes (ATG to 
TTG) would have little or no impact on LAT’s anti-apoptosis 
activity thus confirming that none of the eight potential LAT 
proteins was critical for LAT’s anti-apoptosis activity and 
hence LAT’s ability to enhance the reactivation phenotype.
If interpretation of the results are artificially restricted 
only to effects on translation of potential LAT proteins, one 
would have to conclude that LAT encodes at least two pro-
teins, one from the exon (ORFs 1 or 2) and one from the be-
ginning of the 2 kb intron (ORFs 3–8). However, other expla-
nations are at least as likely. The single nucleotide changes 
may have affected the overall structure of the LAT RNA thus 
reducing an anti-apoptosis activity that is mediated by a large 
portion of the first 1.5 kb of LAT. The changes may have af-
fected stability of the transcript thus decreasing the steady 
state amount of functional LAT product, regardless of its na-
ture. However, this is unlikely because of the differential ef-
fect of LAT3.3I on caspase 8 versus caspase 9 induced apop-
tosis. Alternatively, LAT may encode numerous miRNAs or 
other small RNAs that have a cumulative affect on suppress-
ing apoptosis. Although none of the mutations introduced 
overlap with the first LAT miRNA reported [17], we have de-
tected two additional small LAT-derived RNAs both of which 
would be affected by the introduced mutations (unpublished). 
It is also possible that one or more as yet undetected small 
splices could fuse some of the ORFs together to generate a 
larger functional protein.
Finally, the ability to block apoptosis induced by caspase 
8 versus caspase 9 appeared similar for each of the plasmids 
except LAT3.3I. This plasmid which is knocked out for ORFs 
3–8 provided partial protection against caspase 8 induced 
apoptosis that was similar to the level of protection provided 
by LAT3.3E, which is knocked out for ORFs 1 and 2. In con-
trast, LAT3.3I provided no apparent protection against cas-
pase 9 induced apoptosis. This suggests that within the first 
1.5 kb of LAT, different LAT regions interfere with apoptosis 
by influencing different parts of the apoptotic pathways.
Inhibiting apoptosis appears to be the most important LAT 
function involved in enhancing the virus’ reactivation phe-
notype since we have shown that two different anti-apopto-
sis genes can restore the wild-type reactivation phenotype to 
a LAT negative virus [20–22 & 28]. Determining if LAT in-
terferes (directly or indirectly) with apoptosis via its RNA or 
via a LAT protein is important to deciphering the molecular 
mechanism(s) by which LAT inhibits apoptosis, thereby en-
hancing the viral reactivation phenotype. This in turn will be 
important for developing a highly efficacious clinical inter-
vention against HSV-1 reactivation and recurrent disease. Re-
gardless of the exact mechanism, the results reported here in-
dicate that very minor changes to the LAT sequence can result 
in significant changes to LAT’s anti-apoptosis activity. 
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